Pathogenetic rationale for prescribing menopausal hormone therapy for systemic sclerosis
Systemic scleroderma (SS) is characterized by dysregulation of the innate and adaptive immune systems, vasculopathy, and generalized fibrosis. As with most autoimmune diseases, women predominate among patients, who get sick 3–14 times more often than men. It is assumed that gender differences and mo...
Saved in:
| Main Authors: | T. S. Panevin, L. P. Ananyeva |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2022-11-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/3220 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Menopausal hormone therapy in systemic lupus erythematosus: Pro et contra
by: T. S. Panevin, et al.
Published: (2023-03-01) -
Specifics of prescribing menopausal hormonal therapy in patients with the anamnestic endometriosis
by: M. I. Yarmolinskaya, et al.
Published: (2021-01-01) -
Changes in menopause-specific quality of life between women with transdermal estradiol versus oral estrogens: results of a randomized controlled trial
by: Ruiyi Tang, et al.
Published: (2025-12-01) -
A Comprehensive Review of Systemic Sclerosis: Diagnosis, Clinical Features and Management Strategies
by: Agnieszka Borowiec, et al.
Published: (2025-02-01) -
Menopausal hormone therapy and heart disease prevention: desired or valid?
by: V. I. Podzolkov, et al.
Published: (2019-06-01)